The Investor
08 Sep 2026, 16:05
BioNTech Stock Falls 4.9% as BMO Capital Downgrades Shares and Cuts Price Target
BioNTech (NASDAQ: BNTX) shares fell 4.9% Tuesday after BMO Capital Markets downgraded the biotechnology company and significantly reduced its price target.
BMO Capital downgraded BioNTech from Outperform to Market Perform and cut its price target to $105 from $128.
BioNTech shares were trading around $98.69, leaving the new $105 target only about 6% above the current market price. By comparison, the previous $128 target represented substantially greater upside.
The downgrade marks a notable shift in BMO’s view of the stock. Moving from Outperform to Market Perform indicates reduced expectations for BioNTech to outperform the broader market, while the $23 reduction in the price target further reflects the analyst’s more cautious assessment.
With BNTX shares down nearly 5% following the rating action, investors will be watching the company’s oncology pipeline and other clinical developments for potential catalysts that could improve its longer-term growth outlook.
BioNTech (NASDAQ: BNTX) shares fell 4.9% Tuesday after BMO Capital Markets downgraded the biotechnology company and significantly reduced its price target.
BMO Capital downgraded BioNTech from Outperform to Market Perform and cut its price target to $105 from $128.
BioNTech shares were trading around $98.69, leaving the new $105 target only about 6% above the current market price. By comparison, the previous $128 target represented substantially greater upside.
The downgrade marks a notable shift in BMO’s view of the stock. Moving from Outperform to Market Perform indicates reduced expectations for BioNTech to outperform the broader market, while the $23 reduction in the price target further reflects the analyst’s more cautious assessment.
With BNTX shares down nearly 5% following the rating action, investors will be watching the company’s oncology pipeline and other clinical developments for potential catalysts that could improve its longer-term growth outlook.
